☆ 4.6 Article

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa

MICROBIOLOGY SPECTRUM (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients

Barbara Balandin et al.

Summary: This study aimed to evaluate the efficacy of ceftazidime/avibactam (C/A) in the treatment of Gram-negative bacterial infections in critically ill patients. The results showed that C/A was effective in treating severe GNB infections, including carbapenem-resistant isolates, in critically ill patients. Combination therapy with C/A did not have a higher clinical response compared to monotherapy. The presence of bacteremia, previous corticosteroid use, and the need for life-supporting therapies were significantly associated with mortality.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Infectious Diseases

In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam

J. Guzman-Puche et al.

Summary: This study describes the emergence of CZA resistance in clinical isolates, which is related to mutations in the bla(KPC) gene. The study identifies new alleles, KPC-94 and KPC-95, that do not cause carbapenem resistance.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

添加到收藏夹

Article Microbiology

Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Enterobacterales Clinical Isolates

Renru Han et al.

Summary: The objective of this study was to evaluate the correlation between inhibitory zones and MIC of ceftazidime-avibactam using different testing methods. The results showed that both Etest and disk diffusion had a high agreement with the reference method, broth microdilution, in determining the susceptibility of Enterobacterales to ceftazidime-avibactam.

MICROBIOLOGY SPECTRUM (2022)

添加到收藏夹

Article Microbiology

Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain

Yuexing Tu et al.

Microbiology Spectrum (2022)

添加到收藏夹

Article Microbiology

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases

Milo Gatti et al.

Summary: Two cases of post-neurosurgical ventriculitis caused by carbapenem-resistant Gram-negative pathogens were successfully treated with high-dose ceftazidime/avibactam. The implementation of a real-time clinical pharmacological advice program, which allowed for the optimization of PK/PD targets at the infection site over time, proved to be very helpful.

MICROORGANISMS (2022)

添加到收藏夹

Article Infectious Diseases

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods

Venere Cortazzo et al.

Summary: This study assessed the comparability of different in vitro susceptibility testing methods for ceftazidime-avibactam and ceftolozane-tazobactam. The results showed that VITEK 2 and ETEST yielded equivalent testing results to the BMD method in a clinical context.

ANTIBIOTICS-BASEL (2022)

添加到收藏夹

Article Infectious Diseases

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa

Arhodoula Papadomanolaki et al.

Summary: In this study, the performance of Vitek 2 and Etest methods for susceptibility testing of two novel antibiotics was compared. The results showed that Vitek 2 had comparable performance to the standard broth microdilution method, while Etest did not meet the performance criteria in some cases. Further studies are needed to assess the reliability of Etest.

ANTIBIOTICS-BASEL (2022)

添加到收藏夹

Article Microbiology

KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate

Agnes B. Jousset et al.

Summary: Resistance to the combination of ceftazidime (CAZ) and avibactam (AVI) is increasing, with a CAZ-AVI-resistant Klebsiella pneumoniae strain reported here. This strain, belonging to the high-risk sequence type 307 (ST307) clone, produces Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC3. The study found that KPC-39 has lost carbapenemase activity but shows increased affinity for CAZ, suggesting potential silent dissemination in European healthcare settings.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System

Romney Humphries et al.

Summary: In this study, Vitek 2 AST-Gram-Negative Ceftazidime/Avibactam test results showed high agreement and accuracy compared to the CLSI BMD reference method, meeting or exceeding FDA and ISO performance criteria for routine CZA susceptibility testing.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

Dan Reynolds et al.

Summary: Pseudomonas aeruginosa is a Gram-negative bacterial pathogen commonly causing nosocomial infections, with increasing trends of antimicrobial resistance. It has various virulence mechanisms like toxin secretion and biofilm formation. Management includes prevention, obtaining cultures, and prompt antimicrobial therapy, sometimes requiring combination therapy.

DRUGS (2021)

添加到收藏夹

Article Microbiology

Molecular Mechanisms Driving the In Vivo Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Xi Li et al.

Summary: The study identified a novel KPC variant, KPC-71, in a clinical CRKP strain, leading to the development of CZA resistance during treatment. The KPC-71 enzyme exhibited higher affinity towards ceftazidime and reduced sensitivity to avibactam, resulting in CZA resistance. This novel variant is the first report of its emergence and clinicians should be aware of the risk of CZA resistance in CRKP strains under treatment pressure.

MSPHERE (2021)

添加到收藏夹

Article Infectious Diseases

Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa

Brice Daragon et al.

Summary: Gradient tests (MIC Test Strip and Etest) and Vitek 2 card XN12 performed the best in determining the susceptibility of P. aeruginosa to ceftolozane/tazobactam, while gradient tests were an acceptable alternative to broth microdilution for assessing the susceptibility to ceftazidime/avibactam.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

Performance Evaluation of the Gradient Diffusion Strip Method and Disk Diffusion Method for Ceftazidime-Avibactam Against Enterobacterales and Pseudomonas aeruginosa: A Dual-Center Study

Jingjia Zhang et al.

Summary: The study evaluated the antimicrobial performance of ceftazidime-avibactam against bacteria and found that the gradient diffusion strip method performed better than the disk diffusion method, meeting the needs of clinical microbiological laboratories.

FRONTIERS IN MICROBIOLOGY (2021)

添加到收藏夹

Article Microbiology

In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018

Yang Yang et al.

Summary: The study found that cefepime-zidebactam exhibited potent activity against almost all Enterobacterales and good activity against P. aeruginosa, while ceftazidime-avibactam showed good in vitro activity against Enterobacterales and P. aeruginosa but less activity against Acinetobacter baumannii. Most of the carbapenem-resistant Enterobacteriaceae isolates were susceptible to cefepime-zidebactam and ceftazidime-avibactam showed good activity against bla(KPC-2)-positive Enterobacterales and carbapenem-resistant P. aeruginosa.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Immunology

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

Johann Motsch et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Microbiology

Antimicrobial Resistance in ESKAPE Pathogens

David M. P. De Oliveira et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

添加到收藏夹

Review Microbiology

Critical analysis of antibacterial agents in clinical development

Ursula Theuretzbacher et al.

NATURE REVIEWS MICROBIOLOGY (2020)

添加到收藏夹

Article Microbiology

Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China

Qi Wang et al.

BMC MICROBIOLOGY (2020)

添加到收藏夹

Review Microbiology

New beta-Lactam-beta-Lactamase Inhibitor Combinations

Dafna Yahav et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

添加到收藏夹

Article Infectious Diseases

Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam

Frieder Schaumburg et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)

添加到收藏夹

Article Infectious Diseases

Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms

E. Wenzler et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

添加到收藏夹

Article Microbiology

Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa

Ryan K. Shields et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections

Matt Shirley

DRUGS (2018)

添加到收藏夹

Article Microbiology

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Helio S. Sader et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2018)

添加到收藏夹

Article Immunology

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

David van Duin et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Infectious Diseases

Multiplex PCR for detection of acquired carbapenemase genes

Laurent Poirel et al.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.